3 Beaten-Down Healthcare Stocks to Buy in August

Healthcare is leading over the last 3 months (+13.10%) but still lags YTD, and the article highlights mega-cap drug makers trading below the SPY despite improving earnings. Eli Lilly reported Q2 2026 revenue of $22.97B (+47.7% YoY) with EPS $8.38 beating the $6.40 estimate and raised full-year revenue outlook to $85–$87B; Johnson & Johnson posted Q1 2026 revenue of $24.06B (+10% YoY) with adjusted EPS $2.70 vs $2.68 and reaffirmed strong growth, alongside a $1.34 quarterly dividend (~3% yield) and 64 straight years of increases; AbbVie grew Q1 2026 revenue to $15B (+12% YoY), with Skyrizi and Rinvoq growth offsetting Humira declines, and raised 2026 adjusted EPS to $14.08–$14.28 while boosting its dividend to $1.73/quarter (~3% yield). Key risks cited are biosimilar erosion (e.g., STELARA down 60% for J&J; Humira pressure for AbbVie; product concentration for Lilly) and litigation overhang (JNJ $330M Q1 charges).

Analysis

The setup is less about a clean “value rotation” and more about earnings durability versus patent-cycle risk. JNJ is the lowest-volatility cash compounder here: if rates stay sticky or growth sectors wobble, its dividend plus oncology mix should attract incremental capital from bond proxies and defensive allocators. ABBV still offers the cleanest earnings re-rating path because its post-Humira transition is now visible enough to support multiple expansion, but the market will pay up only if Skyrizi/Rinvoq keep offsetting legacy erosion without a step-up in SG&A or integration charges.

LLY is the hardest name to underwrite from a risk/reward standpoint despite the strongest operating momentum. The market is already assigning a lot of future obesity/diabetes optionality, so the main upside catalyst is not “good earnings” but evidence that pricing pressure and mix dilution are manageable enough to protect long-duration growth. If management signals that price concessions are becoming structural, the multiple can compress even with strong unit growth; that makes LLY more of a momentum hold than a fresh initiation at current levels.

Second-order, the real winner may be the healthcare complex broadly if rotation continues out of crowded mega-cap tech and into defensive growth. But that move is already partially in the tape after the sector’s recent outperformance, so chasing all three names blindly is lower-conviction than expressing relative value. The contrarian risk is that the market is overpaying for stability just as healthcare faces its own mini-cycle of biosimilar cliffs, litigation, and regulatory timing; if macro growth re-accelerates, the relative bid for defensives can fade quickly over 1-3 months.

Key Decisions for Investors

• Long XLV / short SPY for a 1-3 month rotation trade: favorable if yields stay range-bound and investors continue paying for earnings visibility; stop if SPY leadership broadens beyond AI/mega-cap tech and XLV underperforms by >3-4%.
• Overweight JNJ on dips versus ABBV in a quality-income basket: JNJ has the cleaner balance-sheet and litigation-contained profile, while ABBV carries more single-franchise transition risk; best expressed over the next 2-4 quarters.
• Hold ABBV as the higher-beta earnings compounder, but only on pullbacks: use any post-earnings weakness to add if Skyrizi/Rinvoq growth stays above 20% and EPS guidance is reiterated; thesis breaks if legacy erosion accelerates faster than new-product contribution.
• Do not chase LLY here; prefer a wait-and-see alert until the market tests pricing durability and China/rebate pressure stabilizes. If realized pricing worsens or full-year revenue guidance is not raised again, the multiple can de-rate despite strong top-line growth.
• Contrarian hedge: pair long JNJ with a small short basket in the most crowded defensives if healthcare inflows become consensus-driven. The trade works only if defensives keep outperforming on macro fears; it should be covered on any sharp risk-on rebound.